Brief: ContraFect Announces BARDA Contract Award For Up To $86.8 Million And Provides Business Outlook
11/03/2021 22:42
March 11 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES BARDA CONTRACT AWARD FOR UP TO $86.8
MILLION AND PROVIDES BUSINESS OUTLOOK
* CONTRAFECT CORP - RESULTS FROM PHASE 3 DISRUPT STUDY
INTERIM
FUTILITY ANALYSIS ANTICIPATED IN H2 2021
* CONTRAFECT CORP - EXPECTS TO SELECT AN AMURIN PEPTIDE AS
ITS
NEXT IND CANDIDATE BY END OF 2021
* CONTRAFECT CORP - BELIEVES HOSPITAL BURDEN WILL LIGHTEN
DURING
FIRST HALF OF 2021 AND EXPECTS AN ACCELERATION OF DISRUPT STUDY
ENROLLMENT
Source text for Eikon: ID:nGNXbCxNwx
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370